Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amyloidosis.

Raymond L Comenzo1

  • 1Hematology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. comenzor@mskcc.org

Current Treatment Options in Oncology
|April 18, 2006
PubMed
Summary

Amyloidosis treatment requires identifying abnormal protein types. Stem cell transplant with adjuvant therapy offers durable remissions and organ recovery for AL amyloidosis patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.

CA: a cancer journal for clinicians·2026
Same author

Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies.

Journal of clinical medicine·2025
Same author

Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment.

Blood·2025
Same author

Seeking Amyloidosis Very Early: Free light Chain Differentials and IGLV Gene Use as Screening Variables for Light-chain Amyloidosis in λ Monoclonal Gammopathies.

British journal of cancer research·2025
Same author

Case Report: Avoiding misdiagnosis in amyloidosis-navigating transthyretin genopositivity and monoclonal gammopathy in a patient with advanced heart failure and spinal stenosis.

Frontiers in cardiovascular medicine·2024
Same author

Gene Expression Sets and Renal Profiling from the Renal AL Amyloid Involvement and NEOD00 (RAIN) Trial.

Kidney international reports·2024

Area of Science:

  • Hematology
  • Oncology
  • Protein Misfolding Diseases

Background:

  • Amyloidosis involves abnormal protein deposits compromising organs, leading to potential death.
  • Accurate diagnosis is crucial, as AL amyloidosis can be misdiagnosed when co-occurring with monoclonal gammopathy and hereditary variants.
  • Therapy aims to reduce the amyloidogenic light chain and support organ function.

Purpose of the Study:

  • To outline the diagnostic and therapeutic strategies for systemic AL amyloidosis.
  • To highlight the efficacy of stem cell transplantation and adjuvant therapies.
  • To discuss potential future treatment modalities.

Main Methods:

  • Identification of amyloid protein type is essential for treatment selection.
  • Serum free light chain assay monitors therapeutic response.
  • Risk-adapted melphalan with peripheral blood stem cell transplant (SCT) is a primary treatment modality.
  • Adjuvant therapy with thalidomide and dexamethasone post-SCT enhances response rates.

Main Results:

  • Hematologic response rates reach 75% at 12 months with SCT and adjuvant therapy.
  • Long-term, durable remissions with organ recovery are achievable.
  • Supportive measures are vital for sustaining organ function during treatment.

Conclusions:

  • Systemic AL amyloidosis requires targeted therapy to eliminate the precursor light chain.
  • Stem cell transplant combined with specific adjuvant drugs provides effective treatment.
  • Ongoing research explores novel antibody-based approaches for amyloid imaging and clearance.

Related Experiment Videos